Literature DB >> 24171827

Efficacy of beta blockers in the management of problem behaviours in people with intellectual disabilities: a systematic review.

Frances Ward1, Priyanka Tharian, Meera Roy, Shoumitro Deb, Gemma L Unwin.   

Abstract

Both medication and non-medication based strategies are used in the management of problem behaviours in individuals with intellectual disabilities. Beta-adrenoceptor blocking medications are one group of drugs used for this purpose. However, despite its regular use, the evidence for the efficacy of these drugs for in this context is lacking. A systematic review was conducted to establish the research evidence for the efficacy of beta blockers in problem behaviours in adults and children with intellectual disabilities. Although the research identified supported the efficacy of beta blockers for this indication the overall quality of studies identified was poor and no randomised controlled trials were identified. There is a need for more robust research into the use of beta blockers for people with intellectual disabilities who show problem behaviours.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Autism spectrum conditions; Beta adrenergic blockers; Intellectual disability; Problem behaviours; Propanolol; Self-injurious behaviour

Mesh:

Substances:

Year:  2013        PMID: 24171827     DOI: 10.1016/j.ridd.2013.08.015

Source DB:  PubMed          Journal:  Res Dev Disabil        ISSN: 0891-4222


  3 in total

Review 1.  An update on medication management of behavioral disorders in autism.

Authors:  Danielle A Baribeau; Evdokia Anagnostou
Journal:  Curr Psychiatry Rep       Date:  2014-03       Impact factor: 5.285

Review 2.  Pharmacotherapy of Disruptive Behaviors in Children with Intellectual Disabilities.

Authors:  Gabrielle E Hodgins; Kristen Winsor; Jarrett Barnhill
Journal:  Paediatr Drugs       Date:  2022-07-04       Impact factor: 3.930

Review 3.  Practitioner's review: medication for children and adolescents with autism spectrum disorder (ASD) and comorbid conditions.

Authors:  Christian Popow; Susanne Ohmann; Paul Plener
Journal:  Neuropsychiatr       Date:  2021-06-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.